Determine the necessary mass, volume, or concentration for preparing a solution.
≥98% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Protected from light,Argon charged,Desiccated,Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Edratide (TV 4710) is a synthetic peptide of 19 amino acid based on the complementarity-determining region 1 (CDR1) of a human anti-DNA antibody that expresses a major idiotype denoted 16/6 Id. Edratide reduces the rates of apoptosis ( Apoptosis ) and down-regulates of caspase-8 and caspase-3, up-regulates Bcl-xL. Edratide has the potential for the research of systemic lupus erythematosus (SLE) .
In Vivo
Edratide (20-50 µg; s.c.; once a week for 10 weeks) exerts beneficial effects on SLE is through regulation of gene expression. Edratide (50 μg/mouse; s.c.; 10 weekly) reduces the rates of apoptosis and down-regulates of caspase-8 and caspase-3, up-regulates Bcl-xL in SLE mouse. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 6-7 months female mice (with established SLE)Dosage: 20-50 µg Administration: Subcutaneously injection; once a week for 10 weeks Result: Up-regulated the RNA transcripts of Tnfsf4, Il5ra, Zbtb20, Nid1, down-regulated the transcripts of Tfpi and S100a8. Animal Model: 7-8 months SLE-afflicted BWF1 female miceDosage: 50 μg/mouse Administration: S.c.; 10 weekly Result: Reduced apoptosis, down-regulated caspase-8 and caspase-3, and up-regulated Bcl-xL.
Form:Solid
| Isomeric SMILES | CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H]3CCCN3C(=O)[C@@H]4CCCN4C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CO)NC(=O)[C@H](CC7=CNC8=CC=CC=C87)NC(=O)[C@H](CC9=CC=C(C=C9)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)CN |
|---|---|
| PubChem CID | 16214485 |
| Molecular Weight | 2309.53 |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Solubility | DMSO : 100 mg/mL (43.30 mM; Need ultrasonic) |
|---|---|
| Molecular Weight | 2309.500 g/mol |
| XLogP3 | -4.900 |
| Hydrogen Bond Donor Count | 31 |
| Hydrogen Bond Acceptor Count | 31 |
| Rotatable Bond Count | 68 |
| Exact Mass | 2309.11 Da |
| Monoisotopic Mass | 2308.11 Da |
| Topological Polar Surface Area | 883.000 Ų |
| Heavy Atom Count | 166 |
| Formal Charge | 0 |
| Complexity | 5190.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 17 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 1 |